Â鶹ԭ´´

Pharmaceutical and Healthcare sectors are some of the largest contributors to the global health and economic developments that are performing extremely well with innovation. Research & Development in pharma & healthcare is an integral part to developing new therapies, medicines and drugs that cure, prevent and combat diseases. R&D is one of the pioneering forces to drive inventions in pharma & healthcare sectors. Pharmaceutical and Healthcare sectors are estimated to be valued at more than trillion dollars, so the potential for growth and innovation are vast and varied to benefit all demographics.

The R&D environment for new medicines keeps undergoing a number of changes including, growth of managed care organisations, new market strategies of major firms, indication of R&D costs rising at a rate faster than that of overall inflation and the increased attention focused on the pharmaceutical industry scrutiny by the government. Competition in the research based pharmaceutical industry centres on the introduction of new drug therapies; thus, making commercially viable options are not overlooked but expected for overall betterment of healthcare sector.

By the examination of returns on R&D for new drugs introduced, a company can safely invest and plan for future developments without worries of the unpredictable economies. Particularly the evidence of above average expected returns gained, produces rapid increases in industry R&D expenditures, as organizations compete to exploit these opportunities until the returns become common. There is the improved and efficient process practiced of inputting and analyzing the data that is accumulated after the study. This methodology helps in segregation and precise improvement in different drug entities.

Pharma & Healthcare Research & Development Trends

Today pharmaceutical and healthcare organizations are challenged to develop new drugs that address unmet patient needs and deliver demonstrable value in return. The R&D process in the pharmaceutical industry is undergoing unprecedented change as with increased cost pressures, growing consumer demand for variety of personalized medicine and the proliferation of product and patient data, pharmaceutical executives are re-evaluating R&D models. In order for a commercial operation to commence and steadily maintain the organization; transforming and better aligning of R&D Ìýare the most important aspects to look at as companies are looking to harness vast amounts of data to support their most critical clinical and regulatory decisions.

There is a need to leverage the extensive technology enabled health analytics and services that are capable to help organizations demonstrate the various values of products at the earliest stage of the commercialization process so the comparative process is analyzed. Apart from healthcare value assessments, in which there is the study and understanding of cost and benefit of drug treatment to optimize drug development in mass number with support and compliance from regulatory bodies, there is an extensive investment done on clinical trials, where the systematic support of patient protocols and feasibility are measured.

There is a huge market in countries such as Russia, Brazil, China and India, where there are numerous opportunities and the scope for growth is immense. To address R&D needs, organizations dig deep into comprehensive and deep patient centred demographics across the world along with diseased patient databases that will give a unique benchmark and large medical databases. The future viability of pharma & healthcare R&D is focused on advances in healthcare and pharma industry; the objective is to increase substantial and quality of innovative and cost-effective new medicines without incurring greater R&D costs.

Major Pharma R&D Players

Major players, in R&D (Pharma & Healthcare) are Pfizer, Johnson & Johnson, Bayer Healthcare, Eli Lily, Abbot Technologies, Novartis and Sanofi.

Ìý